Axsome Therapeutics (AXSM) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
2 Nov, 2026Executive summary
Q3 revenue was $259.7M, up 52% YoY and 19% sequentially; annualized commercial revenue run rate exceeded $1B.
AUVELITY led commercial growth, while development advanced across CNS indications, including seven Phase 3 trials.
Financial highlights
Q3 product sales were $250.0M and royalty plus milestone revenue was $9.7M, including an $8.5M SUNOSI milestone; total revenue was $259.7M versus $171.0M a year earlier.
AUVELITY sales were $207.6M, up 53% YoY; SUNOSI revenue was $48.2M, up 47%; SYMBRAVO sales were $3.9M, up 88%.
R&D expense was $50.6M versus $40.2M; SG&A was $203.1M versus $150.2M; cost of revenue was $17.8M versus $11.9M.
Net loss narrowed to $12.9M, or $0.25/share, from $47.2M, or $0.94/share; Q3 loss included $26.4M of stock-based compensation.
Outlook and guidance
No specific Q4 or 2027 revenue guidance; Q4 was tracking to expectations for continued AUVELITY growth across MDD and Alzheimer’s agitation.
Cash is expected to fund anticipated operations into cash flow positivity under the current operating plan; R&D and SG&A expenses are expected to rise as trials and commercialization continue.
AUVELITY gross-to-net discounts were in the mid-to-high 40% range in Q3, with a slight Q4 increase expected from seasonal accruals; 2027 is expected to be similar to 2026.
Milestones include ENGAGE BED results in Q1 2027, AXS-12 FDA action by May 1, 2027, and multiple solriamfetol and AXS-05 readouts in 2H 2027.
Latest events from Axsome Therapeutics
- AUVELITY momentum and a deep pipeline frame a $260M-revenue quarter.AXSM
3rd Annual Guggenheim Healthcare Innovation Conference - Auvelity’s launch and pipeline expansion underpin an expected next phase of growth.AXSM
H.C. Wainwright 28th Annual Global Investment Conference - AUVELITY's growth accelerates in new indications, with strong pipeline and financial outlook.AXSM
Morgan Stanley 24th Annual Global Healthcare Conference - AUVELITY's commercial expansion and deep pipeline position the company for strong near-term growth.AXSM
12th Annual Cantor Fitzgerald Global Healthcare Conference - AUVELITY's growth accelerates with new indications and strong pipeline progress, supported by solid financials.AXSM
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue grew 46% to $218.4M, led by AUVELITY's Alzheimer's launch and pipeline progress.AXSM
Q2 2026 - AUVELITY's ADA approval and robust commercial strategy drive $8B peak sales outlook.AXSM
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Late-stage CNS pipeline targets high unmet needs with strong data and major commercial potential.AXSM
R&D Day 2025 - Symbravo gains FDA approval for acute migraine, offering rapid, sustained relief and broad market potential.AXSM
FDA Announcement